Medicines List

Select category
  • Description

    Ambroxol is a mucolytic agent that causes increased secretion of the respiratory tract. It causes increasing production of pulmonary surfactant and stimulates ciliary activity. As a result, there is an increasing of mucus flow and transport (mucoceles clearance) and facilitation of the  expectoration and cough.

    Indications

    -  Secretolytic therapy of acute and chronic bronchopulmonary diseases associated with defective secretion and transport of bronchial mucous.

    Subject to medical prescription

    Pharmaceutical form: 30 mg x 20 effervescent tablets

    ambrin_bg_30mg
  • Description

    Risperidone is a selective monoaminergic antagonist with high affinity for serotoninergic 5-HT2 and dopaminergic D2-receptors. It connects more with alpha 1-adrenergic receptors and lower affinity with H1-histaminergic and alpha 2-adrenergic receptors. He has no affinity for cholinergic receptors. These properties determine the low incidence of extrapyramidal side effects and extends the therapeutic effect of negative and affective symptoms of schizophrenia.

     

     

    Indications

    –  Treatment of a broad spectrum of schizophrenic patients – first psychotic episode, relapses, chronic schizophrenia and other psychotic conditions in which positive symptoms (such as hallucinations, delusion, disturbed thinking, hostility, distrust) and/or negative symptoms (such as affective flattening, emotional and social reticence, impaired verbal fluency) are pronounced. It alleviates affective symptoms (such as depression, guilt, anxiety) associated with schizophrenia.

    –  Resperon is also indicated for long term treatment for prevention of relapse in patients with chronic schizophrenia.

    –  Resperon is indicated for treatment of mania in bipolar affective disorder. These episodes are characterized by elevated, expansive, or irritable mood state, high self-esteem, decreased need for sleep, pressure of speech, accelerated thought processes, lower attention span, impaired judgment, aggressive and/or destructive behavior.

    Subject to medical prescription

    Pharmaceutical form: 2 mg x 20 film-coated tablets

    NHIF code: NF 528

    ICD: F20.0, F20.1, F20.5, F20.6, F31.0, F31.1, F31.2

    Pharmaceutical form: 3 mg x 20 film-coated tablets

    NHIF code: NF 529

    ICD: F20.0, F20.1, F20.5, F20.6, F31.0, F31.1, F31.2

    resperon_bg_2mg
  • Description

    Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure.

    Indications

    – All grades of essential hypertension

    – All classes of heart failure

    – Left ventricular dysfunction after acute myocardial infarction

    – Some types of renovascular hypertension.

    The product is intended for adult patients.

    Subject to medical prescription

    Pharmaceutical form: 5 mg x 30 tablets

    NHIF code: CF 264

    ICD: I10, I11.0, I11.9, I12.0, I12.9, I13.0, I13.1, I13.2, I50.0, I50.1

    Pharmaceutical form: 10 mg x 30 tablets

    NHIF code: CF 265

    ICD: I10, I11.0, I11.9, I12.0, I12.9, I13.0, I13.1, I13.2, I50.0, I50.1

    Pharmaceutical form: 20 mg x 30 tablets

    NHIF code: CF 372

    ICD: I10, I11.0, I11.9, I12.0, I12.9, I13.0, I13.1, I13.2, I50.0, I50.1

    enalapril_bg_10mg
  • Description

    Letrozole is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery.

    Indications

    -  Adjuvant treatment of postmenopausal women with positive breast cancer for hormone receptors, at an initial stage.

    -  Late adjuvant treatment of early hormone-dependent breast cancer in postmenopausal women who have previously received standard adjuvant  tamoxifen therapy for 5 years.

    -  First- line treatment in postmenopausal women with advanced hormone-dependent breast cancer.

    -  Treatment in postmenopausal women (natural or artificially induced menopause) with advanced breast cancer, with recurrence or progression of the disease after antiestrogens treatment.

    The efficacy has not been demonstrated in patients with hormone receptor negative breast cancer.

    Subject to medical prescription

    Pharmaceutical form: 2.5 mg x 30 film-coated tablets

    NHIF code: LF 115

    ICD: C50.0; C50.1; C50.2; C50.3; C50.4; C50.5; C50.6; C50.8; C50.9

    letrofermin_bg_2.5mg